Type 1 Diabetes
Conditions
Brief summary
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Interventions
DRUGHigh Dose SAB-142
High Dose SAB-142
DRUGLow Dose SAB-142
Low Dose SAB-142
OTHERPlacebo
Placebo
Sponsors
SAb Biotherapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
5 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
1. Participant and/or appropriate legal guardian for participants below the legal age of consent must have given written informed consent and/or assent according to local, regional and/or country specific guidance before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. Participants and legal guardians must be capable of providing informed consent and not be incapacitated. 2. Males and females 15-40 years old at the time of randomisation in Part A. Males and females 5-40 years old\*, inclusive, at the time of randomisation in Part B. 3. Weight ≥16.0 kg at time of randomisation. Participants age 18-40 will have a body mass index (BMI) from 16 to 32 (inclusive). 4. Participant has received a diagnosis of T1D according to American Diabetes Association criteria within 100 days of randomization. For participants who were initially misdiagnosed with Type 2 diabetes, time from misdiagnosis with Type 2 diabetes to randomization is 100 days. Note: Unless previously diagnosed with preclinical (Stage 1 or Stage 2 T1D), participant must have initiated insulin therapy by the time of randomisation. An extension of no more than 14 days is permitted if a participant has planned and/or is required to receive a vaccination within 30 days prior to randomisation or is completing the 10 day CGM period. 5. Participant has random C-peptide levels of ≥0.2 nmol/L, measured during Screening. One random C-peptide retest during screening period is allowed. 6. Participant completed all scheduled samples for C-peptide collected during the MMTT test during Screening. 7. Participant has a positive result on testing for at least one of the following T1D-related autoantibodies during screening: * Glutamic acid decarboxylase 65 (GAD65) * Islet antigen 2 (IA-2) * Zinc transporter 8 (ZnT8) * Insulin autoantibodies (if testing within the first 14 days of insulin treatment) 8. Female participants: a. Must be of nonchildbearing potential, i.e., pre-pubertal\*, surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy) at least 6 weeks before the screening, or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle stimulating hormone (FSH) level consistent with postmenopausal status, per local laboratory guidelines), or b. If of childbearing potential, must: i. Have a negative result on a serum (beta human chorionic gonadotropin \[β-HCG\]) at screening and a negative urine β-HCG pregnancy test prior to study drug administration on Day 1 of both treatment periods. ii. Agree not to become pregnant or donate ova from the time of signing the consent form until the end of study visit. iii. If not exclusively in a same-sex relationship or abstinent as a committed lifestyle, must agree to use adequate contraception (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception from the time of signing the consent and for the duration of the study. \* Note: Female participants will be considered to be pre-pubertal (and of nonchildbearing potential) if they have not yet started menstruation. This should also be verified by the parent(s)/guardian(s). If a female participant reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forwards, and contraceptive requirements will apply. 9. Male participants, if not biologically or surgically sterilised, must: 1. Agree not to donate sperm from the time of signing the consent form until EOS. 2. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom combined with use of a highly effective method of contraception from time of signing the consent form until EOS. 3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom from signing the consent form until EOS. 10. Prior to receiving study drug, participant must agree to receive locally, regionally and/or country-specific required age-appropriate immunisations. Participants are advised but not required to comply with the guidelines for immunosuppressed individuals and those with chronic disease (diabetes mellitus) according to current local, regional and/or country- specific guidelines. Note: Vaccines are permitted within the timeframes specified in exclusion criterion #17. 11. Participant agrees not to receive other forms of experimental treatment from the time of signing informed consent and for the duration of the study, particularly agents that may be immune modulatory in nature and/or stimulate pancreatic β cell regeneration or insulin secretion. 12. Participant has suitable venous access for blood sampling. 13. Participant is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions. 14. Part C: Participant has completed Month 12 assessments for Part A and Part B and meets all applicable eligibility requirements for participation in Part C.
Exclusion criteria
1. Participant has known allergy, hypersensitivity or moderate to severe allergic reaction including anaphylaxis to natural or recombinant antibodies, biologic treatments, passive vaccines, pork, or any other component of the study drug formulation (including biologic medications). This includes participants with Hereditary Fructose Intolerance. 2. Participant has a known allergy or hypersensitivity to any of the protocol-required concomitant medications. 3. Participant has been an active participant in a therapeutic drug, invasive medical device, or vaccine clinical trial within 12 weeks before Screening Visit (SV) 2 (Parts A and B) or 28 days prior to Day 1, TP3 (Part C) 4. Participant has received teplizumab or any investigational immunomodulatory anti-CD3 treatment within any timeframe prior to screening. 5. Participant has a significant uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, neurologic, haematologic, rheumatologic, oncologic, psychiatric, or immune deficiency that may interfere with the participant's safely participating in the study or with interpretation of the safety and/or efficacy profile of investigational medicinal product (IMP). For any disorders, a participant with a stable, well-controlled condition that is not felt to interfere with study participation may be enrolled. 6. Participant has any autoimmune disease other than T1D (e.g., rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, systemic lupus erythaematous) that is currently managed with systemic immunotherapy, with the exception of clinically stable thyroid or celiac disease. 7. Participant is prone to infections, or has chronic, recurrent or opportunistic infectious disease, including but not limited to renal, respiratory or skin infections, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis. 8. Participant has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV)-1 or 2, hepatitis B virus (HBV), or hepatitis C virus (HCV) antibodies. 9. Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing. Note: Blood testing (e.g., QuantiFERON® TB Gold test) is strongly preferred; if not available, any local approved TB test is allowed. 10. Serious systemic viral, bacterial, or fungal infection (e.g., pneumonia, pyelonephritis), infection requiring hospitalization or IV anti-infective treatments or significant acute or chronic viral (including history of recurrent or active herpes zoster, acute or active cytomegalovirus \[CMV\], Epstein-Barr Virus \[EBV\] as determined at screening), bacterial, or fungal infection (e.g., osteomyelitis) 30 days before and during screening. Note: Participants with confirmed active EBV or CMV infection based on polymerase chain reaction (PCR) test can be retested; asymptomatic participants with the most recent PCR-negative test are eligible for participation. Participants with an active mild infection at Screening may be enrolled once the symptoms have resolved and all I/E are met. Participants who have an active infection and/or fever ≥38.0°C (100.4°F) within the 48 hours prior to dose administration should not be dosed. 11. Participant has a diagnosis of significant liver disease or at screening ALT and/or AST \>2× or total bilirubin of \>1.5× of the age- and sex-specific upper limit of normal (ULN) according to the central laboratory and confirmed by repeated tests. Liver function tests can be repeated during screening and if normalised, participant maybe eligible for randomization. Note: Participants with Gilbert's syndrome are allowed to enroll if only total and/or indirect bilirubin are elevated above ULN while ALT, AST, and alkaline phosphatase (ALP) are within the normal laboratory ranges. 12. An individual has any of the following haematologic parameters, confirmed by repeat tests, during Screening: * Lymphocyte count: \<1000/μL * Neutrophil count: \<1500/μL * Platelet count: \<100 000 platelets/μL * Haemoglobin: \<10 g/dL Note: Specific haematologic, oncologic or other systemic conditions that might otherwise result in exclusion and/or is heretofore unrecognised should be considered in individuals who have one or more blood cell counts below or above the normal ranges. 13. Current or prior (within 5× half-lives before SV2 for Parts A and B, or within 5x half-lives of Day 1 TP3 for Part C) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including systemic glucocorticoids, verapamil, baricitinib, and others. Note: Inhaled and topical corticosteroids are allowed. Short courses, i.e., approximately 2 weeks or less, of systemic corticosteroids for transient conditions are allowed. 14. Current or prior (within 5× half-lives before SV2 for Parts A and B, or within 5x half-lives of Day 1 TP3 for Part C) use of drugs other than insulin to treat hyperglycaemia (e.g., metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, glucagon-like peptide 1 agonists \[glucagon-like peptide-1\], dipeptidyl peptidase-4 \[DPP-IV\] inhibitors, or amylin). 15. Current or prior (within 5× half-lives before SV2 for Parts A and B, or within 5x half-lives of Day 1 TP3 for Part C) use of any medication known to significantly influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, niacin). 16. Current or planned highly restrictive dietary regimen(s) that would interfere with participant well-being or impact to investigational drug. 17. Recent or planned vaccinations as follows: Countries within EU member states only: * Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox): From 30 days before dosing through 6 months following administration or SAB-142 for each TP. * Recombinant, inactivated or otherwise "non-live" vaccines: From 30 days before dosing or within 60 days following dosing; or planned/required within 30 days prior to or 60 days following Day 1 of TP2. All other countries: * Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox): Within the 30 days before dosing or within 30 days following dosing; or planned/required within 30 days following Day 1 of each TP. * Recombinant, inactivated or otherwise "non-live" vaccines: Within the 30 days before dosing before dosing or within 30 days following dosing; or planned/required within 30 days prior to or 30 days following Day 1 of TP. 18. Female is lactating and/or plans to lactate with the intent to provide her own breast milk to a baby at any point during the study. 19. An individual who has a history of alcohol, drug, or chemical abuse within 12 months prior to study screening (positive tetrahydrocannabinol is allowed) Note: Abuse is defined according to local, regional and/or country specific guidance. Participants who are tested positive for illicit substances but have a prescription medication to manage their concomitant conditions such as attention-deficit/hyperactivity disorder (ADHD) or others are allowed to participate in the study. 20. An individual who has a medical, psychological or social condition that, in the opinion of the Investigator, would interfere with safe and proper completion of the trial. 21. An individual who is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site. 22. An individual who is considered failing to thrive or extremely obese may be excluded based on assessment by the PI, or if participation in the study may place the participant at risk. 23. An individual who has been placed in an institute by official or court order.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) | From dose administration through Week 4 | — |
| Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) | From dose administration up to Month 12 | This is a measure of endogenous insulin production and β cell function (change from baseline in C-peptide ln \[AUC+1\] at 12 months) |
| Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT). | Baseline and Month 24 | This is a measure of endogenous insulin production and β-cell function (change from baseline in C-peptide ln \[AUC+1\] at 24 months versus control). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time in tight range (TITR) | At baseline, Months 3, 6, 9, 12, 18 and 24 | Expressed as a daily average of the percentage of time in a 24hour day a participant's glucose is \>70 but ≤140 mg/dL (\>3.9 to ≤7.8 mmol/L), assessed using continuous glucose monitoring (CGM) |
| Haemoglobin A1c (HbA1c) levels | At baseline, Months 3, 6, 9, 12, 18 and 24 | Expressed in % and mmol/mol |
| Time in range (TIR) | At baseline, Months 3, 6, 9, 12, 18 and 24 | Expressed as a daily average of the percentage of time in a 24-hour day a participant's CGM reading is \>70 but ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L), assessed by CGM |
| Time above range, assessed by CGM | At baseline, Months 3, 6, 9, 12, 18 and 24 | — |
| Time below range, assessed by CGM | At baseline, Months 3, 6, 9, 12, 18 and 24 | — |
| Exogenous insulin use | At baseline, Months 3, 6, 9, 12, 18 and 24 | Defined as a daily average in units per kilogram per day (U/kg/day) (total daily insulin based on participant's diary at predefined study periods) |
| Number of clinically important episodes | At baseline, Months 3, 6, 9, 12, 18 and 24 | Defined as the total number of Level 2 and 3 hypoglycaemic events and/or episodes of cognitive impairment requiring external assistance for recovery (participant's diary and CGM-based) |
| Proportion of participants with partial clinical remission | At baseline, Months 3, 6, 9, 12, 18 and 24 | Defined as an insulin requirement of \<0.25 units per kg of body weight per day and HbA1c \<6.5% (47 mmol/mol) |
| Proportion of participants with partial remission | At baseline, Months 3, 6, 9, 12, 18 and 24 | Defined as insulin-dose adjusted A1c (IDAA1c) + \[4 × insulin dose (units per kilogram per 24 h) ≤9 |
| Total BETA-2 score, comprised of fasting plasma glucose (mmol/L), HbA1c (%), daily insulin (U/kg), and fasting C-peptide (nmol/L) | At baseline, Months 3, 6, 9, 12, 18 and 24 | — |
| Insulin dose-adjusted A1c (IDAA1C) | At baseline, Months 3, 6, 9, 12, 18 and 24 | — |
| Incidence of TEAEs, AESIs, and SAEs | From dose administration through Month 24 | — |
| SAB-142 serum concentrations | Days 1 and 2 of each treatment period (pre- and post- dose/end of infusion [EOI]), plus Weeks 1, 4, and Months 3, 6, 7, 9, 12, 18 and 24 | — |
| Incidence of anti-SAB-142 antibodies including optional neutralising antibodies (nAbs) in serum | At baseline, Weeks 1 and 4, Months 3, 6, 7, 9, 12, 18 and 24 | — |
| Titres of anti-SAB-142 antibodies including optional neutralising antibodies (nAbs) in serum | At baseline, Weeks 1 and 4, Months 3, 6, 7, 9, 12, 18 and 24 | — |
| Immunophenotyping (IPT) | At baseline (Day 1, pre-dose), Week 4, Months 3, 6, 7, 9,12, 18 and 24 | — |
Countries
Australia, Austria, Belgium, Denmark, Finland, France, Germany, Italy, Lithuania, New Zealand, Poland, Slovenia, Spain, United Kingdom, United States
Contacts
CONTACTSenior Manager Clinical Operations
Outcome results
None listed